Oct, 2012
News / Press Releases
Astellas Enters License Agreement with Janssen to Develop and Commercialize ASP015K, an Astellas' Oral JAK Inhibitor for Immunologic Diseases (pdf 26KB)
Read More
Apr, 2024
Apr, 2024
Feb, 2024
Nov, 2023
Mar, 2024
Feb, 2024
Oct, 2023
Sep, 2023
Nothing Found
Unfortunately, we weren't able to find a match for your search query. Please try again.
Nothing Found
Unfortunately, we weren't able to find a match.